Skip to main content
NuCana plc logo

NuCana plc — Investor Relations & Filings

Ticker · NCNA ISIN · US67022C2052 LEI · 213800K5NF92PPHPA304 US Manufacturing
Filings indexed 269 across all filing types
Latest filing 2026-05-14 Foreign Filer Report
Country GB United Kingdom
Listing US NCNA

About NuCana plc

https://www.nucana.com/

NuCana plc is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. The company utilizes its proprietary ProTide technology, a phosphoramidate chemistry platform, to develop a portfolio of new anti-cancer medicines. This technology is designed to generate more effective and safer therapies by overcoming key cancer cell resistance mechanisms that often limit the efficacy of widely prescribed chemotherapy agents. NuCana's pipeline includes novel drug candidates, such as NUC-7738, which are being evaluated for a broad range of cancers, both as standalone treatments and in combination with other therapies like immunotherapy.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2026-05-14 English
6-K - NuCana plc (0001709626) (Filer)
Foreign Filer Report
2026-05-06 English
3 - NuCana plc (0001709626) (Issuer)
Director's Dealing
2026-03-24 English
3 - NuCana plc (0001709626) (Issuer)
Director's Dealing
2026-03-20 English
3 - NuCana plc (0001709626) (Issuer)
Director's Dealing
2026-03-19 English
S-8 - NuCana plc (0001709626) (Filer)
Registration Form
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.